【About Our Speaker】十秒速看講者懶人包

🎓台大獸醫學士➡德州農工大學獸醫病理學博士➡從此踏上獸醫界學術之旅

🩺曾任賓州大學臨床病理學助理教授

💉現任臨床獸醫病理學家、德州農工大學助理教授

📌研究方向：生物資訊、人工智慧於獸醫學和數位細胞學應用

🎙2023年台灣生技協會醫學人工智慧研討會成員，並主持熱門webinar「如何使用AI高效閱讀和撰寫學術文章」

【About Our Speaker】Candice P. Chu, DVM, PhD, DACVP (Veterinary Clinical Pathologist & Assistant Professor at Texas A&M University)

Dr. Chu is a board-certified veterinary clinical pathologist and an assistant professor at Texas A&M University. She began her academic journey with a DVM degree from National Taiwan University, followed by a PhD in veterinary pathology and residency training at Texas A&M University. Before her current position, she was an assistant professor of clinical pathology at the University of Pennsylvania. Her research focuses on integrating bioinformatics, artificial intelligence in veterinary medicine, and digital cytology. She was a panelist at the 2023 Taiwan America Association for Biotechnology Symposium on AI in Medicine and hosted a popular webinar on "How to Efficiently Read and Write Papers Using Digital Tools and AI."

🧑‍🔬Hsin-Yi在台北醫學大學取得醫學檢驗暨生物技術學士，隨後在德州農工大學獲得生物技術碩士，目前她所在的CHO Plus是一家專門利用創新的細胞工程技術來增強治療蛋白和病毒的生產的新創生技公司。本次Webinar她將分享如何將自己在穩定的cell line生成、培養基策略優化、蛋白質純化等方面的專長，發揮到優化蛋白質生產流程。

👨‍🔬Shu-Hong 是休士頓原產地製造，MD Anderson Cancer Center的癌症生物學博士！他精通生物資訊學、流行病學方法和機器學習，目前為BioNTech US的計算生物學Senior Scientist，領導整合多種數據集以推動TCR T細胞療法，以及帶領評估AI演算法在研究和業務操作中的應用。除此之外，他也曾任國家癌症研究所(National Cancer Institute, NCI)的博士後研究員，期間在核苷酸逆轉錄酶抑制劑(NRTI)安全性的研究已在多份著名期刊上發表。

🧑‍🔬Wei-An畢業於成功大學醫學檢驗生物技術學系，並於喬治亞理工學院取得生物資訊學碩士。目前她在波士頓的Vedanta Biosciences擔任生物資訊學Senior Research Associate，專注於微生物組基因組分析和活體生物治療藥物的發現。

想了解位於生技重鎮的灣區的新創生技公司工作是甚麼樣子嗎？你也有想將所學知識奉獻給生技領域的熱情嗎？掌握業界渴求的技術卻渾然不知？想知道在美國取得學位後如何受到生技重鎮的公司賞識嗎？請不要錯過本年度第一場的TTBA Webinar！

【About Our Speaker】Tsai-Yu Chen Ph.D.(Senior Scientist, Process Development, Lonza Houston Inc.)

Dr. Tsai-Yu Chen currently serves as a senior scientist in Process Development, Cell and Gene Technologies division at Lonza. He obtained his Ph.D. in Cancer Biology from The University of Texas MD Anderson Cancer Center / UT Health Graduate School of Biomedical Sciences in 2017. With a focus on mammalian and insect-cell based viral vector production systems, Dr. Chen possesses extensive expertise in various cell and gene therapy applications, such as Adeno-Associated Virus (AAV), Adenovirus, Lentivirus, Vesicular stomatitis virus, and Exosome Production. Transitioning from academic research to industry, Dr. Chen emphasizes the importance of developing scalable processes from the academic setting to cGMP manufacturing as one of the key steps for the commercialization of cell and gene therapy products. In his current role, he leads a cross-functional team to develop cGMP-compliant processes for several prominent global biotech companies, enabling the production of cutting-edge cell and gene therapy products.